FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048290994> ?p ?o ?g. }

• W3048290994 endingPage "204.e7" @default.
• W3048290994 startingPage "204.e1" @default.
• W3048290994 abstract "BackgroundThe Fetal Medicine Foundation proposed a competing risks model for early identification of women at a high risk of preterm preeclampsia, typically associated with deep placentation disorders. The Great Obstetrical Syndromes include a spectrum of pregnancy complications (preeclampsia, intrauterine growth restriction, preterm birth, late spontaneous abortion, and abruptio placentae) that are also associated with deep placentation disorders.ObjectiveThis study aimed to estimate the rate of placenta-mediated pregnancy complications in nulliparous women with a positive first-trimester Fetal Medicine Foundation preterm preeclampsia screening test.Study DesignWe conducted a prospective cohort study of nulliparous women recruited at 11 to 14 weeks of gestation. Maternal characteristics, mean arterial blood pressure, levels of maternal serum biomarkers (pregnancy-associated plasma protein-A, placental growth factor, and soluble fms-like tyrosine kinase-1), and mean uterine artery pulsatility index were obtained to calculate the risk of preterm preeclampsia according to the Fetal Medicine Foundation algorithm. The predicted risks were dichotomized as a positive or negative test according to 2 risk cutoffs (1 in 70 and 1 in 100). The detection rate, false-positive rate, and positive and negative predictive values were calculated for placenta-mediated complications, including preeclampsia, small for gestational age (birthweight <10th percentile), fetal death, preterm birth, and a composite outcome, including any of the foregoing. The same analyses were computed for a composite of severe outcomes, including preterm preeclampsia, severe small for gestational age (less than third percentile), and fetal death.ResultsWe included 4575 participants with complete observations, of whom 494 (10.8%) had an estimated risk of preterm preeclampsia of ≥1 in 70 and 728 (15.9%) had a risk of ≥1 in 100. The test based on a risk cutoff of 1 in 70 could have correctly predicted up to 27% of preeclampsia, 55% of preterm preeclampsia, 18% of small for gestational age, 24% of severe small for gestational age, and 37% of fetal deaths at a 10% false-positive rate. The test based on a cutoff of 1 in 100 could have predicted correctly up to 35% of preeclampsia, 69% of preterm preeclampsia, 25% of small for gestational age, 30% of severe small for gestational age, and 53% of fetal deaths at a 15% false-positive rate. The positive predictive value of a screening test for preterm preeclampsia of ≥1 in 70 was 3% for preterm preeclampsia, 32% for the composite outcome, and 9% for the severe composite outcome.ConclusionNulliparous women with a first-trimester positive preterm preeclampsia Fetal Medicine Foundation screening test are at a higher risk of both preterm preeclampsia and other severe placenta-mediated pregnancy complications. Approximately 1 woman of 10 identified as high risk by the Fetal Medicine Foundation algorithm developed at least 1 severe placenta-mediated pregnancy complication. The Fetal Medicine Foundation proposed a competing risks model for early identification of women at a high risk of preterm preeclampsia, typically associated with deep placentation disorders. The Great Obstetrical Syndromes include a spectrum of pregnancy complications (preeclampsia, intrauterine growth restriction, preterm birth, late spontaneous abortion, and abruptio placentae) that are also associated with deep placentation disorders. This study aimed to estimate the rate of placenta-mediated pregnancy complications in nulliparous women with a positive first-trimester Fetal Medicine Foundation preterm preeclampsia screening test. We conducted a prospective cohort study of nulliparous women recruited at 11 to 14 weeks of gestation. Maternal characteristics, mean arterial blood pressure, levels of maternal serum biomarkers (pregnancy-associated plasma protein-A, placental growth factor, and soluble fms-like tyrosine kinase-1), and mean uterine artery pulsatility index were obtained to calculate the risk of preterm preeclampsia according to the Fetal Medicine Foundation algorithm. The predicted risks were dichotomized as a positive or negative test according to 2 risk cutoffs (1 in 70 and 1 in 100). The detection rate, false-positive rate, and positive and negative predictive values were calculated for placenta-mediated complications, including preeclampsia, small for gestational age (birthweight <10th percentile), fetal death, preterm birth, and a composite outcome, including any of the foregoing. The same analyses were computed for a composite of severe outcomes, including preterm preeclampsia, severe small for gestational age (less than third percentile), and fetal death. We included 4575 participants with complete observations, of whom 494 (10.8%) had an estimated risk of preterm preeclampsia of ≥1 in 70 and 728 (15.9%) had a risk of ≥1 in 100. The test based on a risk cutoff of 1 in 70 could have correctly predicted up to 27% of preeclampsia, 55% of preterm preeclampsia, 18% of small for gestational age, 24% of severe small for gestational age, and 37% of fetal deaths at a 10% false-positive rate. The test based on a cutoff of 1 in 100 could have predicted correctly up to 35% of preeclampsia, 69% of preterm preeclampsia, 25% of small for gestational age, 30% of severe small for gestational age, and 53% of fetal deaths at a 15% false-positive rate. The positive predictive value of a screening test for preterm preeclampsia of ≥1 in 70 was 3% for preterm preeclampsia, 32% for the composite outcome, and 9% for the severe composite outcome. Nulliparous women with a first-trimester positive preterm preeclampsia Fetal Medicine Foundation screening test are at a higher risk of both preterm preeclampsia and other severe placenta-mediated pregnancy complications. Approximately 1 woman of 10 identified as high risk by the Fetal Medicine Foundation algorithm developed at least 1 severe placenta-mediated pregnancy complication." @default.
• W3048290994 created "2020-08-13" @default.
• W3048290994 creator A5003276368 @default.
• W3048290994 creator A5004593543 @default.
• W3048290994 creator A5008590532 @default.
• W3048290994 creator A5059435570 @default.
• W3048290994 creator A5075639462 @default.
• W3048290994 date "2021-02-01" @default.
• W3048290994 modified "2023-10-16" @default.
• W3048290994 title "Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study" @default.
• W3048290994 cites W1154833837 @default.
• W3048290994 cites W1980268488 @default.
• W3048290994 cites W2006314446 @default.
• W3048290994 cites W2020310037 @default.
• W3048290994 cites W2034492080 @default.
• W3048290994 cites W2106356304 @default.
• W3048290994 cites W2137966156 @default.
• W3048290994 cites W2260113709 @default.
• W3048290994 cites W2340668831 @default.
• W3048290994 cites W2520664488 @default.
• W3048290994 cites W2569868133 @default.
• W3048290994 cites W2730504020 @default.
• W3048290994 cites W2735078930 @default.
• W3048290994 cites W2738449290 @default.
• W3048290994 cites W2744484065 @default.
• W3048290994 cites W2756176199 @default.
• W3048290994 cites W2767859123 @default.
• W3048290994 cites W2769242542 @default.
• W3048290994 cites W2773800864 @default.
• W3048290994 cites W2781814244 @default.
• W3048290994 cites W2811016670 @default.
• W3048290994 cites W2895485671 @default.
• W3048290994 cites W2896452076 @default.
• W3048290994 cites W2944730273 @default.
• W3048290994 cites W2947734442 @default.
• W3048290994 cites W2972142796 @default.
• W3048290994 cites W2978654833 @default.
• W3048290994 cites W3002210726 @default.
• W3048290994 cites W3016100831 @default.
• W3048290994 cites W3017350989 @default.
• W3048290994 cites W3022893079 @default.
• W3048290994 cites W4235754528 @default.
• W3048290994 cites W4252813748 @default.
• W3048290994 doi "https://doi.org/10.1016/j.ajog.2020.08.008" @default.
• W3048290994 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32777265" @default.
• W3048290994 hasPublicationYear "2021" @default.
• W3048290994 type Work @default.
• W3048290994 sameAs 3048290994 @default.
• W3048290994 citedByCount "13" @default.
• W3048290994 countsByYear W30482909942021 @default.
• W3048290994 countsByYear W30482909942022 @default.
• W3048290994 countsByYear W30482909942023 @default.
• W3048290994 crossrefType "journal-article" @default.
• W3048290994 hasAuthorship W3048290994A5003276368 @default.
• W3048290994 hasAuthorship W3048290994A5004593543 @default.
• W3048290994 hasAuthorship W3048290994A5008590532 @default.
• W3048290994 hasAuthorship W3048290994A5059435570 @default.
• W3048290994 hasAuthorship W3048290994A5075639462 @default.
• W3048290994 hasBestOaLocation W30482909941 @default.
• W3048290994 hasConcept C126322002 @default.
• W3048290994 hasConcept C131872663 @default.
• W3048290994 hasConcept C172680121 @default.
• W3048290994 hasConcept C188816634 @default.
• W3048290994 hasConcept C201903717 @default.
• W3048290994 hasConcept C2776953305 @default.
• W3048290994 hasConcept C2777218350 @default.
• W3048290994 hasConcept C2777583542 @default.
• W3048290994 hasConcept C2778376644 @default.
• W3048290994 hasConcept C2779234561 @default.
• W3048290994 hasConcept C2780938740 @default.
• W3048290994 hasConcept C29456083 @default.
• W3048290994 hasConcept C45167389 @default.
• W3048290994 hasConcept C46973012 @default.
• W3048290994 hasConcept C54355233 @default.
• W3048290994 hasConcept C71924100 @default.
• W3048290994 hasConcept C86803240 @default.
• W3048290994 hasConceptScore W3048290994C126322002 @default.
• W3048290994 hasConceptScore W3048290994C131872663 @default.
• W3048290994 hasConceptScore W3048290994C172680121 @default.
• W3048290994 hasConceptScore W3048290994C188816634 @default.
• W3048290994 hasConceptScore W3048290994C201903717 @default.
• W3048290994 hasConceptScore W3048290994C2776953305 @default.
• W3048290994 hasConceptScore W3048290994C2777218350 @default.
• W3048290994 hasConceptScore W3048290994C2777583542 @default.
• W3048290994 hasConceptScore W3048290994C2778376644 @default.
• W3048290994 hasConceptScore W3048290994C2779234561 @default.
• W3048290994 hasConceptScore W3048290994C2780938740 @default.
• W3048290994 hasConceptScore W3048290994C29456083 @default.
• W3048290994 hasConceptScore W3048290994C45167389 @default.
• W3048290994 hasConceptScore W3048290994C46973012 @default.
• W3048290994 hasConceptScore W3048290994C54355233 @default.
• W3048290994 hasConceptScore W3048290994C71924100 @default.
• W3048290994 hasConceptScore W3048290994C86803240 @default.
• W3048290994 hasFunder F4320314210 @default.
• W3048290994 hasIssue "2" @default.
• W3048290994 hasLocation W30482909941 @default.
• W3048290994 hasOpenAccess W3048290994 @default.
• W3048290994 hasPrimaryLocation W30482909941 @default.

• next